急性早幼粒细胞白血病巩固治疗现状及进展

The Treatment and Progress in Consolidation Therapy of APL

急性早幼粒细胞白血病(APL)曾被认为是最迅速的致命白血病,特点为临床表现凶险,早期死亡率高,治愈率低。药物全反式维甲酸及亚砷酸的应用,使APL的治疗取得了很大成功,其完全缓解率可达90%。然而APL的复发率仍然较高,约15%-30%。降低复发率和提高长期生存已成为研究重点,如何选择合理的缓解后治疗策略至关重要。缓解后治疗一般包括巩固治疗和维持治疗,而最佳治疗方案的确定仍然有待商榷。因此,本文就APL缓解后巩固治疗回顾相关文献进行整合分析,综述APL巩固治疗的研究进展。

Acute promyelocytic leukemia （APL） was considered to be the most rapidly fatal leukemia, because of serve clinical manifestation, high rate of early death and the low cure rate. APL has achieved great success due to the application of ATRA and ATO. Although the complete remission rate is about 90%, the relapse rate has been reported to be as high as 15%-30%. So reducing the recurrence and improving long-time survival have become the focus of the study. Choosing the reasonable treatment after remission is very important. The post remission therapy usually include consolidation therapy and maintenance therapy,but the optimal strategy has been controversy. Therefore, this artical will review the literature of APL in consolidation therapy.